|
A Message from Autonomix
Autonomix is aiming to shrink today’s diagnostic lab equipment down to the size of a two-millimeter microchip placed on a catheter that can detect and target nerve signals.
And you can invest before their planned Nasdaq listing.
This potentially groundbreaking technology is intended to be the equivalent of a GPS for the nervous system, which could unlock new treatments for everything from high blood pressure to pain. Imagine treating pain by altering the nerves instead of relying on prescriptions like opioids.
Autonomix’s tech has over 100 patents, a strong edge against potential copycats as they tackle this estimated $100B market opportunity.
While they plan to list on the Nasdaq, our readers don’t have to wait until then to invest. Become an Autonomix shareholder today. |
